Big Promises Backed by Bad Theory
By Eric Hoffman and Stuart Newman,
Genetic Engineering & Biotechnology News
| 05. 15. 2012
Synthetic biology is the newest purported cure-all technology for remedying our social, environmental, and public health ills. As many prominent synthetic biologists proclaimed in 2007, the world “face[s] daunting problems of climate change, energy, health, and water resources. Synthetic biology offers solutions to these issues…Fifty years from now, synthetic biology will be as pervasive and transformative as is electronics today.”i
Bold claims aside, the basic assumption behind synthetic biology—that organismal complexity can be remolded with predictable outcomes using simplistic engineering tools and standardized parts—may divert scientific research and funding away from programs more beneficial to the advancement of science and the public good. In addition, the undeniable power of the technology to alter living systems also contains potential for harm.
Synthetic biology is a collection of techniques and agendas (both research and business) that includes:
- Genome-driven cell engineering: the substitution of chemically synthesized DNA or DNA analogues for their natural counterparts in order to change cell behavior and/or produce novel products;
- DNA-based device construction: the construction of DNA sequences that encode protein or RNA molecules that assemble into complex...
Related Articles
By Rachel Hall, The Guardian | 11.20.2025
Couples are needlessly going through IVF because male infertility is under-researched, with the NHS too often failing to diagnose treatable causes, leading experts have said.
Poor understanding among GPs and a lack of specialists and NHS testing means male infertility...
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Pam Belluck and Carl Zimmer, The New York Times | 11.19.2025
Gene-editing therapies offer great hope for treating rare diseases, but they face big hurdles: the tremendous time and resources involved in devising a treatment that might only apply to a small number of patients.
A study published on Wednesday...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...